(UroToday.com) Dr. Axel Bex presents his take on the management of metastatic clear cell RCC with systemic therapy, with or without delayed nephrectomy – specifically focusing on the when and how. As the primary author of the SURTIME Study,1 he can speak to the literature with great authority.